Human lipoprotein-associated phospholipase A2,Lp-PLA2 ELISA Kit

Instructions
Code CSB-E08319h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
Alternative Names Platelet-activating factor acetylhydrolase precursor ELISA Kit; 1 alkyl 2 acetylglycerophosphocholine esterase ELISA Kit; 1-alkyl-2-acetylglycerophosphocholine esterase ELISA Kit; 2 acetyl 1 alkylglycerophosphocholine esterase ELISA Kit; 2-acetyl-1-alkylglycerophosphocholine esterase ELISA Kit; EC 3.1.1.47 PAF acetylhydrolase PAF 2-acylhydrolase LDL associated phospholipase A2 ELISA Kit; Group VIIA phospholipase A2 ELISA Kit; Group-VIIA phospholipase A2 ELISA Kit; gVIIA PLA2 ELISA Kit; gVIIA-PLA2 ELISA Kit; LDL associated phospholipase A2 ELISA Kit; LDL PLA(2) ELISA Kit; LDL PLA2 ELISA Kit; LDL-associated phospholipase A2 ELISA Kit; LDL-PLA(2) ELISA Kit; Lipoprotein associated phospholipase A2 ELISA Kit; LP PLA2 ELISA Kit; PAF 2 acylhydrolase ELISA Kit; PAF 2 acylhydrolase LDL associated phospholipase A2 ELISA Kit; PAF 2-acylhydrolase ELISA Kit; PAF acetylhydrolase ELISA Kit; PAFA_HUMAN ELISA Kit; PAFAD ELISA Kit; PAFAH ELISA Kit; Phospholipase A2, group VII (platelet activating factor acetylhydrolase, plasma) ELISA Kit; PLA2G7 ELISA Kit; Platelet activating factor acetylhydrolase 2 ELISA Kit; Platelet activating factor acetylhydrolase ELISA Kit; Platelet-activating factor acetylhydrolase ELISA Kit
Abbreviation PLA2G7
Uniprot No. Q13093
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 1.56 ng/mL-100 ng/mL
Sensitivity 0.39 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Metabolism
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
             
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human Lp-PLA2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:5 Average % 93  
Range % 90-96  
1:10 Average % 91  
Range % 87-96  
1:20 Average % 97  
Range % 93-100  
1:40 Average % 89  
Range % 85-96  
Recovery
The recovery of human Lp-PLA2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 93 90-96  
EDTA plasma (n=4) 95 90-101  
             
             
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected  
100 2.767 2.861 2.814 2.642  
50 2.356 2.313 2.335 2.163  
25 1.672 1.638 1.655 1.483  
12.5 0.983 0.972 0.978 0.806  
6.25 0.657 0.635 0.646 0.474  
3.12 0.455 0.444 0.450 0.278  
1.56 0.279 0.286 0.283 0.111  
0 0.170 0.173 0.172    
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids.
Gene References into Functions
  1. The decrease of Lp-PLA2 activity in adolescents with type 2 diabetes suggests that elevated blood glucose concentrations do not have a dominant elevating effect, perhaps even a decreasing influence on Lp- PLA2 activity. PMID: 29027597
  2. Polymorphisms in rs1805017 and rs1805018, additional interaction between rs1805017 and smoking, and haplotype containing the rs1805017-H and rs1805018-T alleles were associated with increased CHD risk. PMID: 29728838
  3. CD163 positive macrophages have roles in lipoprotein-associated phospholipase A2 activity in atherosclerotic plaque PMID: 29101839
  4. evidence that Lp-PLA2 could predict all-cause mortality and rehospitalization risk among patients with ACS undergoing PCI. PMID: 29121808
  5. the relationship between two variants of apoC1 and the risk of polycystic ovary syndrome, evaluated the genotypic effects on clinical, hormonal and metabolic indexes and plasma platelet-activating factor acetylhydrolase (PAF-AH) activity, was investigated. PMID: 29636060
  6. Met117 oxidation caused enhanced flexibility and decreased compactness in oxidized state. PAF binding interaction with oxidized protein was mediated only through hydrophobic interactions. PMID: 29427679
  7. Persistently elevated serum concentrations of Lp-PLA2 were associated with an unfavorable outcome in patients with sepsis. PMID: 29138849
  8. Resveratrol downregulates Lp-PLA2 expression by inhibiting oxidative stress via SIRT1 pathway in the THP-1-derived macrophages. PMID: 28608449
  9. Elevated Lp-PLA2 mass was associated with all cause-death independently of other risk factors within one year after acute ischemic stroke. PMID: 28934604
  10. PLA2G7 and PON1 are overexpressed in prostatic neoplasm patients and can be detected early in blood. PMID: 29050675
  11. A PLA2G7 gene polymorphism determines the plasma levels of lipoprotein-associated phospholipase A2 activity and mass and manifests as a risk factor for atherosclerosis. PMID: 27905470
  12. Conclusion RBP4 may be used as a predictive factor of diabetic nephropathy patients complicated with silent cerebral infarction (SCI) and is positively correlated with cognitive dysfunction. RBP4/Lp-PLA2/Netrin-1 pathway activation may be one of the occurrence mechanisms in diabetic nephropathy complicated with SCI. PMID: 28704853
  13. Greater Lp-PLA2 activity or mass was associated with an increased risk of CHD and IS PMID: 28514697
  14. Lp-PLA2 G994T gene polymorphism may be an independent risk factor of ischemic stroke in Chinese population. PMID: 28960681
  15. Lifelong lower Lp-PLA2 activity was not associated with major risks of vascular or non-vascular diseases in Chinese adults. PMID: 27301456
  16. phospholipase A2 Group 7 (PLA2G7), to be important in regulating tumor cell migration and a novel tumor-promoting factor in nasopharyngeal carcinoma. PMID: 27487154
  17. Suggest that the plasma biomarkers Lp-PLA2 activity and mass are markers of abdominal aortic aneurysm risk after adjusting for relevant confounders. PMID: 28475940
  18. The substitution of whole grains and legumes for refined rice resulted in a reduction in Lp-PLA2 activities in plasma and PBMCs partly through improved glycemic control, increased consumption of protein relative to carbohydrate, and reduced lipid peroxides. PMID: 24904022
  19. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease PMID: 28502488
  20. High levels of high-sensitive C-reactive protein and lipoprotein-associated phospholipase-A2 did not relate to endothelial dysfunction in ST-elevation myocardial infarction patients treated with percutaneous coronary intervention. PMID: 28110894
  21. In persistent prehypertension, increased ox-LDL hydrolysis by Lp-PLA2 enhances arterial stiffness without an age-related increase in blood pressure. PMID: 28142077
  22. LpPLA2 is found in both LDL and HDL and is distributed differently in men with T1D without any relationship to CAC score progression PMID: 27206945
  23. In a multi-ethnic cohort without baseline cardiovascular disease, higher Lp-PLA2 mass and activity were not significantly associated with an increased risk for incident peripheral arterial disease. PMID: 28215109
  24. Lipoprotein-associated phospholipase A2 as a new marker to determine cardiovascular risk in hypercholesterolemic dyslipidaemic children PMID: 27614353
  25. The simultaneous presence of the PLA2G7 279VV genotype and persistence of overweight synergistically increases the risk for hypertension. PMID: 28334001
  26. Elevated mass and activity of Lp-PLA2 related to inflammation and atherosclerosis may take part in the development of kidney injury and atherosclerosis in patients with chronic kidney disease. PMID: 27776715
  27. Taken together, these results revealed that Lp-PLA2 silencing protected against ox-LDL-induced oxidative stress and cell apoptosis via Akt/mTOR signaling pathway in human THP1 macrophages. PMID: 27392709
  28. Plasma Lp-PLA2 concentration was independently associated with coronary heart disease in Chinese patients. PMID: 28222638
  29. The distribution of V279F-AA+AC genotype and R92H-AA+AG genotype in the AP group was higher than that in the control group, whereas the Severity of Acute Pancreatitis (SAP) group and SAP with multiple organ dysfunction syndrome group distributions were higher than those in the MAP group and SAP without MODS group.G-C-A, G-A-G, and G-C-G haploids formed by A379V, V279F, and R92H may be associated with AP susceptibility PMID: 28332853
  30. results do not support added value of Lp-PLA2 for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor PMID: 27097870
  31. High Lp-PLA2 expression is associated with type 1 diabetes. PMID: 27710915
  32. This presentation aims at clarifying the involvement of Lp-PLA2 in the pathophysiology of atherosclerosis, and at assessing its interest both as a biomarker for the onset of CV events and as a therapeutic target--{REVIEW} PMID: 26499399
  33. PLA2G7 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
  34. A considerable portion of Chinese ischemic stroke patients are insensitive to aspirin treatment, which may be correlated with the MDR1 C3435T, TBXA2R (rs1131882), and PLA2G7 (rs1051931-rs7756935) polymorphisms. PMID: 27641736
  35. Uremic environment but not inflammation per se increases plasma Lp-PLA2 activity and upregulates monocytic Lp-PLA2 mRNA expression. The highest Lp-PLA2 levels were found in the classical and not in the inflammatory subsets. Atherosclerosis also contributes to a subset-specific increase in Lp-PLA2 mRNA expression. PMID: 27992874
  36. Lp-PLA2 levels in human plasma were positively associated with the severity of coronary heart disease. PMID: 27941334
  37. Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with coronary heart disease, particularly in patients with stable coronary heart disease who were not receiving therapies for inhibiting Lp-PLA2.[review] PMID: 27956130
  38. Expression of LpPLA2 may be associated with obesity. Therefore, LpPLA2 mRNA expression levels may develop as an important risk predictor for vascular complications in Metabolic syndrome. PMID: 26460076
  39. PLA2G7 gene expression was co-regulated by 17-beta-estradiol and promoter methylation. PMID: 27450918
  40. no relationship with either proinflammatory cytokines or neopterin identified in Alzheimer disease PMID: 26828804
  41. Lp-PLA2 activity in Japanese men aged 50-79 years was associated significantly and positively with IMT and plaque in the carotid artery but Mendelian randomization did not support that Lp-PLA2 is a causative factor for subclinical atherosclerosis. PMID: 26775119
  42. 279Val-->Phe Polymorphism of Lp-PLA2 may lead to decrease the enzymatic activity via changes of folding kinetics and recognition to its substrate. PMID: 26595893
  43. Increased plasma Lp-PLA2 activity portends increased risk of resistant hypertension. PMID: 26801405
  44. These findings suggest that plasma PAF may be a potential biomarker for predicting poor bone health in postmenopausal women. PMID: 25501698
  45. Studied whether the level of Lp-PLA2 is associated with subclinical atherosclerosis in patients with rheumatoid arthritis. PMID: 26504820
  46. Higher Lp-PLA2 mass and activity were associated with development of both incident clinical peripheral arterial disease and low ankle brachial index. PMID: 26848158
  47. A V279F loss-of-function variant in the PLA2G7 gene resulting in 50% lower activity for each copy of the variant, is common in East Asians and associated with risk of Vascular diseases. PMID: 26791069
  48. It is assumed that Lp-PLA2 is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 itself. PMID: 25458708
  49. Cytosolic phospholipase A2 modulates TLR2 signaling in synoviocytes. PMID: 25893499
  50. Lipoprotein associated phospholipase A2 activity and apolipoprotein C3 loss-of-function variants are involved in cardiovascular disease PMID: 26117401
  51. The study indicated that the A379V variant in PLA2G7 gene might contribute to ischemic stroke susceptibility in northern Chinese Han population. PMID: 24463064
  52. The presence of subclinical coronary atherosclerosis is associated independently with Lp-PLA2, and it has potential utility as a novel indicator of cardiovascular disease risk in the young adult population. PMID: 25647459
  53. In multi-ethnic cohort, Lp-PLA2 was positively associated with CVD risk, regardless of the presence of coronary artery calcium or a thickened carotid-intimal media. PMID: 26004387
  54. miR-183 and miR-205 failed to detect early and aggressive PCa despite their highly dysregulated expression in cancer tissue PMID: 25581763
  55. Lp-PLA2 concentrations were positively associated with all LDL subfractions and small HDL subfraction, suggesting an interaction between Lp-PLA2 and lipoprotein subfraction phenotypes in the status of coronary artery disease. PMID: 25934512
  56. Higher levels of Lp-PLA2-A in the acute period after TIA or minor stroke are associated with increased short-term risk of recurrent vascular events. PMID: 26311748
  57. Data suggest that sub-acute autoimmune inflammatory disease progresses independently of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity. PMID: 25874928
  58. Lp-PLA2 and TNF-alpha are significantly increased in thalassemia children and show strong correlations with carotid intima-media thickness. PMID: 25056687
  59. circulating CETP and Lp-PLA2 might partly play a role in the atherogenic disturbances in patients with iron deficiency anemia through increased susceptibility to lipid peroxidation PMID: 26642708
  60. These findings indicated that R92H variant in PLA2G7 gene might contribute to CHD susceptibility in a southern Chinese population. PMID: 25690150
  61. in high-risk coronary artery disease patients of European ancestry, the PLA2G7 rs1805017 GG genotype is associated with increased Lp-PLA2 plasma activity and acute myocardial infarction PMID: 24732951
  62. the natural absence of the plasma Lp-PLA2 activity due to carriage of the Lp-PLA2 279FF genotype may reduce the generation of lysoPC (16:0) and oleamide and thereby enhance the activity of plasma tryptophan in normal physiological processes PMID: 25078067
  63. lipoprotein-associated phospholipase A2 has a role in silent brain infarcts in women PMID: 25463126
  64. LpPLA2 mass was not associated with coronary or carotid subclinical atherosclerosis in retired NFL players. PMID: 25105582
  65. A reduction in oxidative stress was seen in Korean subjects carrying the 379V allele of the Lp-PLA 2 gene. PMID: 24682749
  66. after clopidogrel and cilostazol combination therapy, galectin-3 level, lipoprotein-associated phospholipase A2 gene expression, and RhoA/ROCK-related protein expression in peripheral blood mononuclear cells were significantly suppressed PMID: 24742198
  67. Lp-PLA2 may play an important role in the pathogenesis of atherosclerosis PMID: 24492522
  68. Blood LP-PLA2 level was inversely related to impaired glucose metabolism in patients with stable vascular disease. PMID: 24930071
  69. Inhibition of PAF acetylhydrolase resulted in inhibition of breast cancer cell adherence. PMID: 25186013
  70. In our study, we found that PLA2G7 variants that reduce lipoprotein-associated phospholipase A2 activity to a degree similar to activity associated with darapladib have no effect on the risk of coronary heart disease. PMID: 25587968
  71. Administration of omega-3 PUFA can decrease Lp-PLA2 in patients with stable angina undergoing percutaneous coronary intervention. PMID: 24555913
  72. Data suggest that, two years after delivery, plasma levels of PLA2G7 and advanced glycation end products are up-regulated in women who had gestational diabetes; these levels may be biomarkers of increased risk for metabolic/cardiovascular diseases. PMID: 24397392
  73. Lp-PLA2 mass and activity could provide different information in the hyperacute stage of stroke PMID: 24513482
  74. Small, dense LDL and Lp-PLA2 concentrations are increased independently in the end stage renal failure patients who are receiving dialysis treatment. PMID: 25291938
  75. Data suggest plasma Lp-PLA2 is upregulated in elderly subjects, in subjects with type 2 diabetes, and is further upregulated in subjects treated for severe aortic stenosis with TAVI (transcatheter aortic valve implantation)/BA (balloon angioplasty). PMID: 24818163
  76. In smokers a further effect of raised oxidative stress is the up-regulation of Lp-PLA2 expression in PBMC with subsequent increase of plasma Lp-PLA2 and lysophosphatidylcholine. PMID: 24358251
  77. It was concluded that Lp-PLA2 may be a new useful biomarker to evaluate clinical or subclinical activity of the disease besides CRP and ESR PMID: 22755553
  78. LpPLA2-mass levels were associated with risk of atherosclerotic stroke among non-Hispanic White participants, but not in other race-ethnic groups in the cohort. PMID: 24416164
  79. Increased Lp-PLA2 levels are associated with an increased risk of re-stenosis. PMID: 24580749
  80. Blood serum levels of LP-PLA2 in a healthy Chinese Han population. PMID: 24393260
  81. Significant associations between serial changes in Lp-PLA2 activity and changes in fibrous cap thickness and plaque volume were observed in patients with acute coronary syndromes. PMID: 24089018
  82. The reduced levels of Lp-PLA2 and suPAR in human carotid plaques of subjects on long-term treatment with beta-blockers suggest their possible protective role in plaque inflammation. PMID: 23747086
  83. relative increase of apoB/Lp-PLA2 in hypercholesterolemic patients PMID: 24092915
  84. Taken together, our findings uncover an unanticipated tumor suppressive role for PLA2R1 that is mediated by targeting downstream JAK2 effector signaling. PMID: 24008317
  85. Lp-PLA2 levels are significantly associated with coronary heart disease. PMID: 23103135
  86. Lp-PLA2 is highly expressed in CAVD, and it plays a role in the mineralization of valve interstitial cells. PMID: 24161325
  87. There was no significant association between baseline Lp-PLA2 quartiles and risk of venous thromboembolism. PMID: 23746626
  88. PLA2G7 gene promoter methylation increases the risk of coronary heart disease in females PMID: 23555769
  89. Darapladib produced sustained inhibition of Lp-PLA2 activity in Japanese dyslipidemic patients with/without the V279F SNP of Lp-PLA2. PMID: 23439604
  90. Prediabetes patients have significantly decreased high-density lipoprotein-LP-PLA2 activity compared with subjects with glucose levels <100 mg/dL. PMID: 23546765
  91. SAA up-regulates Lp-PLA2 production significantly via a FPRL1/MAPKs./PPAR-gamma signaling pathway. PMID: 23623642
  92. PLA2G7 expression is elevated in colon tumors compared with normal tissues. PMID: 23361301
  93. Lp-PLA2 activity changes in obesity and it shows important associations with markers of cardiovascular risk. PMID: 23413990
  94. Our results demonstrated dynamic alterations in Lp-PLA2 levels during the early stages of ACS and, therefore, indirectly support the hypothesis of an active role for Lp-PLA2 in the pathogenesis of ACS. PMID: 23140470
  95. Lp-PLA2 activity was significantly lower in rare non-synonymous single-nucleotide polymorphisms carriers compared with non-carriers and seven variants had enzyme activities consistent with a null allele. PMID: 21606947
  96. the interaction between recombinant human Lp-PLA(2) and human HDL PMID: 23089916
  97. High Lp-PLA2 activity implies a worse prognosis at long term follow up in high-risk Caucasian patients referred for coronary angiography. PMID: 23118945
  98. variability of Lp-PLA(2) across gender, ethnicity, and levels of circulating lipids and markers of systemic inflammation are more consistent and appear not to vary importantly across categories defined by CVD or its risk factors. PMID: 22784637
  99. aortic valve stenosis (AVS) is characterized by increased plasma Lp-PLA2 levels associated with the severity of AVS PMID: 23089713
  100. The neonates of women with severe preeclampsia had significantly higher plasma PAF-AH levels. PMID: 22797139

Show More

Hide All

Involvement in disease Platelet-activating factor acetylhydrolase deficiency (PAFAD); Asthma (ASTHMA); Atopic hypersensitivity (ATOPY)
Subcellular Location Secreted, extracellular space
Protein Families AB hydrolase superfamily, Lipase family
Tissue Specificity Plasma.
Database Links

HGNC: 9040

OMIM: 147050

KEGG: hsa:7941

STRING: 9606.ENSP00000274793

UniGene: Hs.584823

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1